The Effect of Combination of Mosapride and Dipeptidyl Peptidase-4 (DPP-4) Inhibitor on Plasma Concentration of Incretin Hormones

Trial Profile

The Effect of Combination of Mosapride and Dipeptidyl Peptidase-4 (DPP-4) Inhibitor on Plasma Concentration of Incretin Hormones

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Mosapride (Primary) ; Linagliptin; Paracetamol
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Nov 2017 Status changed from not yet recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top